People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Horizon Pharma, Inc. | — | Pharmaceuticals | Series D+ | $308.4M | $5.3B | 2012 |
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2013 |
| Artax Biopharma, Inc. | — | Biotechnology | Series B | $48.0M | $75.8M | 2014 |
Gino W. Santini at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gino W. Santini on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gino Santini | 2 | 5 |
| David Hirsch | 1 | 16 |
| Peter B. Finn | 1 | 11 |
| Patrick Heron | 1 | 11 |
| Louis C. Bock | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
| John Freund | 1 | 7 |
| Jeffrey W. Bird | 1 | 6 |
| Raj Parekh | 1 | 5 |
| Michael Heffernan | 1 | 5 |
| Casper Breum | 1 | 5 |
| Paul Brannelly | 1 | 4 |
| Eran Nadav | 1 | 4 |
| Steven N. Tannenbaum | 1 | 3 |
| Alan E. Walts | 1 | 3 |
| Timothy P. Walbert | 1 | 3 |
| Alan Walts | 1 | 3 |
| Patrick N. Heron | 1 | 3 |
| Javier Garcia | 1 | 3 |
| Theodore A Schroeder | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.